|
|
Article: KeraCure(TM) Initiates Multi-Center Pivotal Study in Diabetic Foot Ulcers.
- Article from:
- Business Wire
- Article date:
- March 7, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CHICAGO -- KeraCure, Inc. announced today that the first patients have been treated in a Multi-Center Pivotal Study for the treatment of diabetic foot ulcers. The study was recently approved by the Food and Drug Administration (FDA) to test the safety and efficacy of the KeraPac(TM) device in approximately 270 subjects in 16 clinical sites across the U.S. The Company expects to complete enrollment in approximately one year.
KeraCure believes that its KeraPac addresses the primary obstacles that rivals have faced in their bid to penetrate the cell-based dressing segment. The KeraPac focuses on simplicity, low cost, ease of manufacture and off-the-shelf ...